GHDDI announces the progress of self-developed new crown oral drug: it can effectively inhibit virus replication and is expected to enter the clinic in the second half of 2022

[Global Network Comprehensive Report] Due to the advantages of convenient early drug use, low synthesis cost, and room temperature storage, small molecule new crown oral drugs have high hopes in the global anti-epidemic

Since November 2021, new crown oral drugs have been approved for marketing around the world one after another

Another good news came today! On January 25, the Global Health Drug Research and Development Center (GHDDI) announced that its preclinical drug candidate molecule GDI-4405 targeting the novel coronavirus 3CL protease is accelerating multiple clinical trial applications and drug production.

According to reports, 3CL protease, as the main protease of the new coronavirus, is necessary for the replication and growth of the virus, so it is also an excellent antiviral drug target

"The global new crown epidemic continues to develop, and more effective and convenient oral anti-new crown drugs are urgently needed to meet the global drug availability

It is understood that in response to the global outbreak of the new crown epidemic, GHDDI launched drug research and development for the new crown 3CL protease in early 2020, starting from its enzyme function and structure, and through medicinal chemistry, virus biology, structural biology and data science teams.

According to public information, the Global Health Drug Research and Development Center (GHDDI) was co-founded in 2016 by Tsinghua University, the Bill & Melinda Gates Foundation, and the Beijing Municipal Government.